TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients with postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Level of postoperative serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recovery period after complications
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Complications (blisters, teleangiectatic matting, scar formation, bruising)
Endpoint domain: Adverse events/effects
Primary endpoint: total energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical demands
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Distractions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Feeding behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3/4 febrile neutropenia (FN)
Endpoint domain: Adverse events/effects
Primary endpoint: modified Rankin scale (mRS) ≤1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin scale (mRS) ≤2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH Stroke Scale score 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Putaminal DAT binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Striatal asymmetry in DAT binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ratio between caudate DAT and D2 binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiovascular death or worsening heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in KCCQ-TSS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to deterioration in physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to deterioration in role function
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to deterioration in chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Entomological indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cheek volume improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with facial appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Achievement of treatment goals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Size of the dural sac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early postoperative quadriceps dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 24 hrs urinary protein content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum levels of SOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation of arterial blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ratings of product healthfulness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of delayed graft function (DGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: changes in physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total systemic exposure (AUClast) of glycopyrronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance rate (CLr) of glycopyrronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effective volume of rectum irradiated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in hip lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: serum 25(OH) vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iowa Gambling Task performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: increased empathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OHIP-Edent values
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: disease-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: progression in grade and/or stage of the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to therapy with unselected young TILs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to therapy with CD8(+)‐enriched TILs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4(+) peripheral blood lymphocytes count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: self-perception of mental sharpness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cytology accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytology sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytology specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in Doppler E/e' ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of diastolic dysfunction grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time of swelling regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective rate of swelling regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: verbal cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %OSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-exhaustion (TTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive function performance (Stroop test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: length of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on the day of surgery and on days 4 to 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subject comfort during treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improved injection experience
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pocket Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Gingival Enlargement Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Subjective disfigurement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: times to full crusting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: cessation of new lesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 50% reduction in the area of affected skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of SSA/Ps
Endpoint domain: Adverse events/effects
Primary endpoint: Release of CK-MB and cTnI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance for Pap test
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: remission on the MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate (HR) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: S' by TDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: global Sl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: global SRl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in systolic pressure readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Confirmed hypoglycemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute GI toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physical Activity (PA) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness of eating goals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Awareness of physical activity goals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antibiotic therapy duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of combined adverse outcome within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Number of TF expressing platelet-derived MPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transition to skilled nursing facility (SNF)
Endpoint domain: Mortality/survival
Primary endpoint: Modified Berg Balance Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: any high-grade adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: any fatal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of childhood infection
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of adult infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mean oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rates of suicide ideation
Endpoint domain: Adverse events/effects
Primary endpoint: incident CHD
Endpoint domain: Mortality/survival
Primary endpoint: Staff performance rating
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Attitudes regarding knowledge and skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WOMAC index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain visual analogue scale reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in physical capability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to treatment progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gut CD4 T-cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Th22 cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Th17 cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in left ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in end-diastolic volume (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Protective antibody concentrations of at least 0.1 IU/mL for diphtheria and tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean antibody titers to pertussis toxoid and other antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of solicited local and systemic reactions and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Median number of episodes of acid reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median number of episodes of non-acid reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median number of acid-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nasal Airway Resistance (NAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face validity of exercise systems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in recorded exercise times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of exercise errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embolic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Corneal thickness at the clear corneal incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to tumor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of postoperative swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in antibiotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: YGTSS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI activation during finger tapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GR-beta mRNA expression in nasal polyp tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically recurrent IgAN
Endpoint domain: Adverse events/effects
Primary endpoint: Relative bioavailability of aconiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentration of aconiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOLIE‐31‐P)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rx understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: regimen dosing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: regimen consolidation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: nasopharyngeal carriage of pneumococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: concentrations of pneumococcal serotype 6B polysaccharide antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Carbohydrate metabolism (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemostasis system impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Greenough Low Back Outcome Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Kyphosis angle correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mastery motivation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Costs of dressing, labour, analgesics, scar management
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: subjective experience of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Delay of reoccurrence of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Initial hospitalization costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 6-month hospitalization costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Length of initial hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Spinal rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STAI-State/Trait scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HADS-Anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pathological complete response (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: c-myc expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new STDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self-reported 100% condom use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FLACC scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐reported pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline of VAS measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for analgesic 'rescue therapy'
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decrease in TNFα levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Voluntary activation of the quadriceps femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac event‐free survival
Endpoint domain: Mortality/survival
Primary endpoint: laryngitis scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oesophageal symptom score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of (S)-propranolol and (S)-atenolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: norepinephrine levels during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOVA-PR Omissions score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ammonia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of HE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality risk stratification
Endpoint domain: Mortality/survival
Primary endpoint: Inspiratory muscle strength (SPImax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnoea
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: nocturnal oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: apnea/hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: At-risk drinking at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes